Body mass index and chemotherapy completion among patients with newly diagnosed ovarian cancer
Body mass index und Chemotherapie-Vollendung bei Patient:innen mit neu diagnostiziertem Ovarialkarzinom
JNCI Cancer Spectrum · 09.01.2026 · 10 (1)
DOI: 10.1093/jncics/pkaf121 ↗Auf einen Blick
In einer retrospektiven Kohorte war der Relative Dosisintensität bei BMI ≥25 höher als bei BMI <25. Die meisten Dosisanpassungen erfolgten während der Behandlung.
Fragestellung
Zusammenhang von BMI bei Diagnosestellung mit Chemotherapie-Vollendung, Hospitalisierungen und Toxizitäten bei neu diagnostiziertem Ovarialkarzinom.
Methode
Retrospektive Kohortenstudie im Yale-Smilow Cancer Network (2012-2022) bei Patient:innen mit kurativer Carboplatin/Paclitaxel-Therapie; Analyse von BMI, starting RDI und received RDI.
Ergebnisse
327 Patient:innen. Mittlere RDI 79,7 %; 44,3 % lagen unter 85 %. Starting RDI 97,9 % (9,1 %), received RDI 81,8 % (25,7 %). Höherer BMI war mit höherer RDI und received RDI assoziiert.
Schlussfolgerung der Autor:innen
Bei seit 2012 behandelten Patient:innen mit Ovarialkarzinom war die Gesamt-RDI niedrig. Die RDI war bei BMI ≥25 höher als bei BMI <25; die meisten Änderungen traten während der Therapie auf.
Kernaussagen
- BMI ≥25 war mit höherer RDI assoziiert
- 44,3 % hatten eine RDI unter 85 %
- Die meisten Dosisänderungen erfolgten während der Behandlung
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Fachartikel in der Zeitschrift JNCI Cancer Spectrum, online erschienen am 24.12.2025. Verfasst von Anlan Cao und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chronic Disease Epidemiology, Yale School of Public Health, New Haven, CT, United States. Hauptthemen laut MEDLINE: Ovarian Neoplasms, Body Mass Index, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCATS NIH HHS, Claude D. Pepper Older Americans Independence Center at Yale University, NCI NIH HHS.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Several ovarian cancer studies have suggested that a body mass index (BMI) of 30 or higher is associated with lower compliance with National Comprehensive Cancer Network–recommended chemotherapy but primarily involved treatment before 2012, when dose capping was recommended for patients with higher body surface areas. Updated analyses in the contemporary treatment era are warranted.
Methods
In a retrospective cohort of patients with newly diagnosed ovarian cancer receiving curative-intent carboplatin plus paclitaxel in the Yale-Smilow Cancer Network (2012-2022), we evaluated BMI at diagnosis in relation to relative dose intensity (RDI)—the ratio of completed chemotherapy dose intensity to the National Comprehensive Cancer Network–recommended dose intensity—which reflects dose modification both before and during treatment. We also assessed starting RDI (which reflects modifications before treatment) and received RDI (which reflects modifications during treatment). Data on hospitalizations and hematological chemotoxicities were collected. We examined the association between BMI (<25, 25-30, ≥30) and chemotherapy completion, hospitalizations, and toxicities using multivariable linear and logistic regressions.
Results
Among 327 patients, the average RDI was 79.7%, and 44.3% had an RDI below 85%. Mean (SD) starting and received RDI were 97.9% (9.1%) and 81.8% (25.7%), respectively. Higher BMI was associated with higher RDI (Paggregate = .03) and received RDI (Paggregate = .04). Body mass index was not associated with starting RDI, dose reductions, delays, hospitalizations, or hematological toxicities.
Conclusions
Among patients with ovarian cancer treated since 2012, the overall RDI was low. Relative dose intensity was higher among patients with a BMI of 25 or higher compared with a BMI below 25. Most dose modifications occurred during treatment and not before initiation. Studies with body composition data and interventions that maximize chemotherapy completion during treatment are warranted.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Chronic Disease Epidemiology, Yale School of Public Health, New Haven, CT, United States.
- Yale Cancer Center, New Haven, CT, United States.
- Yale School of Medicine, New Haven, CT, United States.
- Department of Biostatistics, Yale School of Public Health, New Haven, CT, United States.
- Sylvester Comprehensive Cancer Center, University of Miami School of Medicine, Miami, FL, United States.
- Department of Obstetrics & Gynecology, University of Miami School of Medicine, Miami, FL, United States.
ORCID-Profile: Anlan Cao, Brenda Cartmel, Fang-Yong Li, Matthew P Schlumbrecht, Amanika Kumar, Tracy E Crane, Denise A Esserman, Melinda L Irwin, Leah M Ferrucci
Förderung
- NCATS NIH HHS
- Claude D. Pepper Older Americans Independence Center at Yale University
- NCI NIH HHS
- National Center for Advancing Translational Science at the National Institutes of Health
- NIA NIH HHS
- National Cancer Institute at the National Institutes of Health
Zitieren
APA
Cao, A., Cartmel, B., Ratner, E., Li, F. Y., Schlumbrecht, M. P., Kumar, A., Crane, T. E., Esserman, D. A., Irwin, M. L., & Ferrucci, L. M. (2026). Body mass index and chemotherapy completion among patients with newly diagnosed ovarian cancer. JNCI Cancer Spectrum, 10(1). https://doi.org/10.1093/jncics/pkaf121
Vancouver
Cao A, Cartmel B, Ratner E, Li FY, Schlumbrecht MP, Kumar A, et al. Body mass index and chemotherapy completion among patients with newly diagnosed ovarian cancer. JNCI Cancer Spectrum. 2026;10(1). doi:10.1093/jncics/pkaf121
BibTeX
@article{Cao2026,
author = {Cao, Anlan and Cartmel, Brenda and Ratner, Elena and Li, Fang-Yong and Schlumbrecht, Matthew P and Kumar, Amanika and Crane, Tracy E and Esserman, Denise A and Irwin, Melinda L and Ferrucci, Leah M},
title = {Body mass index and chemotherapy completion among patients with newly diagnosed ovarian cancer},
journal = {JNCI Cancer Spectrum},
year = {2026},
volume = {10},
number = {1},
doi = {10.1093/jncics/pkaf121}
}
EUVIMED